Prestige Consumer Healthcare (PBH) Amortization of Deferred Charges (2010 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Amortization of Deferred Charges came in at $452000.0 in Q4 2025, up 4.15% year-on-year from $434000.0 in Q4 2024, and up 1.12% quarter-over-quarter from $447000.0 in Q3 2025.
Prestige Consumer Healthcare (PBH) Amortization of Deferred Charges (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Amortization of Deferred Charges history runs 16 years deep, the most recent figure standing at $452000.0 for Q4 2025.
- On a quarterly basis, Amortization of Deferred Charges rose 4.15% year-over-year to $452000.0 in Q4 2025; TTM through Dec 2025 was $1.8 million, a 37.14% decrease from a year earlier, with the FY2025 full-year figure at $1.8 million, down 66.53% from the prior year.
- Amortization of Deferred Charges grew to $452000.0 in Q4 2025 per PBH's latest filing, from $447000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $1.8 million in Q1 2023 and bottomed at $428000.0 in Q3 2024.
- The 5-year median for Amortization of Deferred Charges is $821500.0 (2022), against an average of $916950.0.
- Across the five-year window, Amortization of Deferred Charges jumped 111.37% in 2021 and slumped 71.07% in 2025, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $1.4 million in 2021, then slumped by 40.77% to $815000.0 in 2022, then surged by 74.72% to $1.4 million in 2023, then tumbled by 69.52% to $434000.0 in 2024, then climbed by 4.15% to $452000.0 in 2025.
- Per Business Quant, the three latest PBH Amortization of Deferred Charges figures stand at $452000.0 (Q4 2025), $447000.0 (Q3 2025), and $442000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Prestige Consumer Healthcare | 2.41 Bn | 2.35 Bn | 157.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 452,000.00 |
| Dec 31, 2025 | 452,000.00 |
| Sep 30, 2025 | 447,000.00 |
| Sep 30, 2025 | 447,000.00 |
| Jun 30, 2025 | 442,000.00 |
| Jun 30, 2025 | 442,000.00 |
| Mar 31, 2025 | 438,000.00 |
| Mar 31, 2025 | 438,000.00 |
| Dec 31, 2024 | 434,000.00 |
| Dec 31, 2024 | 434,000.00 |
| Sep 30, 2024 | 428,000.00 |
| Sep 30, 2024 | 428,000.00 |
| Jun 30, 2024 | 454,000.00 |
| Jun 30, 2024 | 454,000.00 |
| Mar 31, 2024 | 1.51 Mn |
| Mar 31, 2024 | 1.51 Mn |
| Dec 31, 2023 | 1.42 Mn |
| Dec 31, 2023 | 1.42 Mn |
| Sep 30, 2023 | 1.32 Mn |
| Sep 30, 2023 | 1.32 Mn |